Role of p21 in prostaglandin A2-mediated cellular arrest and death

M Gorospe1, N J Holbrook

  • 1Section on Gene Expression and Aging, National Institute on Aging, NIH, Baltimore, Maryland 21224, USA.

Cancer Research
|February 1, 1996
PubMed

Insights

Prostaglandin A2 (PGA2) causes growth arrest in some cells by increasing p21, but triggers cell death in others. Lack of p21 leads to cell death, suggesting p21 prevents death from cell cycle issues.

Area of Science:

  • Cell Biology
  • Molecular Biology
  • Cancer Research

Background:

  • Prostaglandin A2 (PGA2) is known to induce growth arrest in various cell types.
  • Previous studies linked PGA2-induced growth arrest in MCF-7 breast cancer cells to p21 induction and decreased cyclin-dependent kinase 2 (CDK2) activity.

Purpose of the Study:

  • To investigate the differential cellular response of RKO cells to PGA2 compared to MCF-7 cells.
  • To elucidate the role of p21 in mediating PGA2's effects on cell cycle progression and cell death.

Main Methods:

  • Treatment of RKO and MCF-7 cells with Prostaglandin A2 (PGA2).
  • Analysis of p21 expression levels and cyclin-dependent kinase 2 (CDK2) activity.
  • Manipulation of endogenous p21 expression in MCF-7 cells using antisense p21.

Main Results:

  • PGA2 treatment failed to induce growth arrest in RKO cells, leading to significant cell death.
  • RKO cells showed no p21 induction and increased CDK2 activity following PGA2 treatment.
  • Reducing p21 in MCF-7 cells mimicked the RKO cell response, causing less growth arrest and more cell death.

Conclusions:

  • The cyclin-dependent kinase inhibitor p21 plays a crucial role in mediating Prostaglandin A2-induced growth arrest.
  • p21 induction by PGA2 appears to prevent inappropriate cell cycle progression and subsequent cell death.
  • Differential p21 expression contributes to varied cellular responses to PGA2, impacting cell fate.

Related Concept Videos

Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...